Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir
Sponsor: Chinese University of Hong Kong
Summary
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the treatment of chronic hepatitis B virus (HBV) infection. TAF has been shown to be a potent inhibitor of HBV replication at a low dose, with high intracellular concentration and more than 90% lower systemic TFV concentration than tenofovir disoproxil fumarate (TDF). TAF has been approved in the clinical practice guidelines in the west. Since its availability in Asia in 2017, there have been evolving data concerning its positive impact on renal safety as shown in registration trials. The primary objective of this study is to compare the risk of chronic kidney disease (CKD) progression in chronic hepatitis B patients on TAF versus ETV in a territory-wide cohort in Hong Kong.
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
1800
Start Date
2022-09-01
Completion Date
2026-12-31
Last Updated
2023-02-08
Healthy Volunteers
No
Conditions
Interventions
Tenofovir alafenamide
Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
Entecavir
Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
Locations (1)
Prince of Wales Hospital
Shatin, Hong Kong